Immunization with pneumococcal polysaccharide serotype 3 and lipopolysaccharide modulates lung and liver inflammation during a virulent Streptococcus pneumoniae infection in mice

Clinical and Vaccine Immunology

Volumn 20, Issue 5, 2013, Pages 639-650

  Restori, Katherine H ^a   Kennett, Mary J ^b   Ross, A Catharine ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDE; MESSENGER RNA; PNEUMOCOCCUS POLYSSACHARIDE SEROTYPE 3 VACCINE; PNEUMOCOCCUS VACCINE; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HEPATITIS; IMMUNIZATION; INOCULATION; LIVER; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAA GENE; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; UPREGULATION;

ACUTE-PHASE PROTEINS; ANIMALS; ANTIBODIES, BACTERIAL; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; IMMUNOGLOBULIN M; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; LUNG; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; POLYSACCHARIDES, BACTERIAL; SERUM AMYLOID A PROTEIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84876831328     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00593-12     Document Type: Article

References (29)

1. World Health Organization. 2007. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly. Epidemiol. Rec. 82:93-104.
2. Haessler S, Schimmel JJ. 2012. Managing community-acquired pneumonia during flu season. Cleve. Clin. J. Med. 79:67-78.
3. Pitsiou GG, Kioumis IP. 2011. Pneumococcal vaccination in adults: does it really work? Respir. Med. 105:1776-1783.
4. Schranz J. 2009. Pneumoccoal conjugate vaccines: what do we know and what do we need? Procedia Vaccinol. 1:189-205.
5. How MJ, Brimacombe JS, Stacey M. 1964. The pneumococcal polysaccharides. Adv. Carbohydr. Chem. 19:303-358.
6. Baker PJ, Amsbaugh DF, Stashak PW, Caldes G, Prescott B. 1981. Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells. Rev. Infect. Dis. 3:332-341.
7. Ferreira DM, Moreno AT, Cianciarullo AM, Ho PL, Oliveira ML, Miyaji EN. 2009. Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microb. Pathog. 47:157-163.
8. Mizrachi-Nebenzahl Y, Lifshiz S, Teitelbaum R, Novick S, Levi A, Benharroch D, Ling E, Dagan R. 2003. Differential activation of the immune system by virulent Streptococcus pneumoniae strains determines recovery or death of the host. Clin. Exp. Immunol. 134:23-31. (Pubitemid 37186583)
9. Pasatiempo AM, Kinoshita M, Foulke DT, Ross AC. 1994. The antibody response of vitamin A-deficient rats to pneumococcal polysaccharide is enhanced though coimmunization with lipopolysaccharide. J. Infect. Dis. 169:441-444. (Pubitemid 24045611)
10. Winter C, Herbold W, Maus R, Länger F, Briles DE, Paton JC, Welte T, Maus UA. 2009. Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J. Immunol. 182:4931-4937.
11. Li J, Szalai AJ, Hollingshead SK, Nahm MH, Briles DE. 2009. Antibody to the type 3 capsular facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages. Infect. Immun. 77:464-471.
12. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25:402-408. (Pubitemid 34164012)
13. Pfaffl MW. 2001. A new mathematical model for relative quantification of real-time RT-PCR. Nucleic Acids Res. 29:2001-2007.
14. Londhe KB, Borlak J. 2012. A cross-platform comparison of genomewide expression changes of laser microdissected lung tissue of c-Raf. PLoS One 7:e40778. doi:10.1371/journal.pone.0040778.
15. Burns T, Abadi M, Pirofski LA. 2005. Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin M monoclonal antibody to serotype 8 capsular polysaccharide. Infect. Immun. 73:4530-4538. (Pubitemid 41105607)
16. Lu YC, Yeh WC, Ohashi PS. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42:145-151.
17. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316:1628-1632. (Pubitemid 46982038)
18. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N. 2009. AS04, an aluminum saltand TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183:6186-6197.
19. Casella CR, Mitchell TC. 2008. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life. Sci. 65:3231-3240.
20. Yuste J, Botto M, Bottoms SE, Brown JS. 2007. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog. 3:e120. doi:10.1371/journal.ppat.0030120.
21. Quinton LJ, Jones MR, Robson BE, Mizgerd JP. 2009. Mechanisms of the hepatic acute-phase response during bacterial pneumonia. Infect. Immun. 77:2417-2426.
22. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. 1986. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261:9644-9651. (Pubitemid 17214087)
23. Eriksen N, Benditt EP. 1980. Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 77:6860-6864. (Pubitemid 11219045)
24. Uhlar CM, Whitehead AS. 1999. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265:501-523. (Pubitemid 29488982)
25. Huttunen T, Teppo AM, Lupisan S, Ruutu P, Nohynek H. 2003. Correlation between the severity of infectious disease in children and the ratio of serum amyloid A protein and C-reactive protein. Scand. J. Infect. Dis. 35:488-490. (Pubitemid 37138948)
26. Lannergård A, Larsson A, Kragsbjerg P, Friman G. 2003. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand. J. Clin. Lab. Invest. 63:267-272. (Pubitemid 37006434)
27. Patel H, Fellowes R, Coade S, Woo P. 1998. Human serum amyloid A has cytokine-like properties. Scand. J. Immunol. 48:410-418. (Pubitemid 28459659)
28. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T. 2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and activator of innate immune response. Nature 448:501-506.
29. Pham HT, Park MY, Kim KK, Kim YG, Ahn JH. 2006. Intracellular localization of human ZBP1: differential regulation by the Z-DNA binding domain, Zα, in splice variants. Biochem. Biophys. Res. Commun. 348:145-152. (Pubitemid 44163493)